IRBP (1-20), human

IRBP (1-20), human is a synthetic peptide corresponding to the N-terminal residues 1 through 20 of human interphotoreceptor retinoid-binding protein (IRBP). As a fragment derived from a key extracellular glycoprotein involved in the visual cycle, this peptide segment is of considerable interest for researchers investigating retinal biochemistry, protein-protein interactions, and the molecular mechanisms underlying visual signal transduction. Its defined sequence and structural properties make it a valuable tool for elucidating the functional domains of IRBP, as well as for mapping antibody epitopes and studying post-translational modifications. The availability of this peptide enables targeted experimental approaches in both basic and applied retinal research.

Epitope mapping: The IRBP (1-20), human peptide serves as a precise substrate for identifying and characterizing antibody binding sites within the N-terminal region of IRBP. Researchers can employ it in immunoassays, such as ELISA or Western blotting, to assess the specificity and affinity of antibodies raised against IRBP or its fragments. By facilitating the mapping of immunodominant epitopes, the peptide supports the development of more selective immunoreagents and enhances the understanding of autoimmune responses implicated in retinal disorders.

Protein-protein interaction studies: As a defined sequence fragment, this peptide is used to probe molecular interactions between IRBP and potential binding partners, including retinoids, lipids, or other extracellular matrix components. Its application in binding assays, surface plasmon resonance, or pull-down experiments enables the dissection of interaction motifs and the identification of critical residues responsible for ligand recognition. Such studies contribute to a deeper comprehension of the role of IRBP in retinoid transport and visual cycle maintenance.

Peptide-based structural analysis: The IRBP (1-20) sequence provides a model system for investigating secondary structure formation and conformational dynamics of the IRBP N-terminus. Researchers can utilize techniques such as circular dichroism spectroscopy, NMR, or computational modeling to analyze the peptide's folding behavior and structural preferences. Insights gained from these analyses inform broader studies of IRBP's functional domains and may guide the design of peptide analogs with modified properties.

Antigenicity assessment: The defined and conserved nature of this N-terminal peptide makes it an effective tool for evaluating antigenic determinants relevant to immune recognition in retinal tissues. By incorporating the peptide into immunization protocols or in vitro T-cell assays, scientists can assess its potential to elicit immune responses, thereby advancing research into the immunopathology of retinal diseases and informing the selection of candidate sequences for further investigation.

Assay development: The IRBP (1-20), human peptide is routinely used as a reference standard or positive control in the development and validation of immunoassays targeting IRBP. Its well-characterized sequence and biochemical properties enable reproducible assay calibration and facilitate the comparison of results across different experimental platforms. This supports the standardization of analytical methods in retinal research, contributing to more robust and interpretable data in studies of IRBP expression, localization, and function.

1. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

2. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die

3. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

4. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

5. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs